These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37471697)

  • 1. Euthyroid Graves' ophthalmopathy.
    Schattner A; Voichanski S; Pollack R; Uliel L
    QJM; 2023 Nov; 116(11):942-943. PubMed ID: 37471697
    [No Abstract]   [Full Text] [Related]  

  • 2. Euthyroid Graves' ophthalmopathy with negative autoantibodies.
    Cakir M
    J Natl Med Assoc; 2005 Nov; 97(11):1547-9. PubMed ID: 16334503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unilateral optic neuropathy as the initial manifestation of euthyroid Graves' disease.
    Arslan E; Yavaşoğlu I; Cildağ BM; Kocatürk T
    Intern Med; 2009; 48(22):1993-4. PubMed ID: 19915303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies targeting the calcium binding skeletal muscle protein calsequestrin are specific markers of ophthalmopathy and sensitive indicators of ocular myopathy in patients with Graves' disease.
    Gopinath B; Musselman R; Beard N; El-Kaissi S; Tani J; Adams CL; Wall JR
    Clin Exp Immunol; 2006 Jul; 145(1):56-62. PubMed ID: 16792674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular Manifestations and Clinical Implications of Serum Immunoglobulin G4 Levels in Graves' Ophthalmopathy Patients.
    Luo B; Yuan X; Wang W; Zhang J; Liu R; Hu W; Qi X; Xiang N; Chen L
    Ocul Immunol Inflamm; 2022 Apr; 30(3):580-587. PubMed ID: 33054491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TSH receptor antibody titers measured with a third-generation assay did not reflect the activity of Graves' ophthalmopathy in untreated Japanese Graves' disease patients.
    Mukasa K; Yoshimura Noh J; Kouzaki A; Ohye H; Kunii Y; Watanabe N; Yoshihara A; Matsumoto M; Suzuki M; Ito K
    Endocr J; 2016; 63(2):151-7. PubMed ID: 26581710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Implications of Immunoglobulin G4 to Graves' Ophthalmopathy.
    Yu SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Thyroid; 2017 Sep; 27(9):1185-1193. PubMed ID: 28805160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Euthyroid Graves' ophthalmopathy in a child.
    Peter S
    West Indian Med J; 2006 Oct; 55(5):360. PubMed ID: 17373308
    [No Abstract]   [Full Text] [Related]  

  • 9. [Graves' ophthalmopathy from the internist's perspective].
    Laubner K; Weber WA; Seufert J
    Ophthalmologe; 2011 May; 108(5):410-6. PubMed ID: 21590351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orbital pseudotumor: a differential diagnosis of Graves' ophthalmopathy.
    Caminha LS; Pinto ER; Sousa PA; Oliveira RA; Conceiçao FL; Vaisman M
    Arq Bras Endocrinol Metabol; 2011 Feb; 55(1):85-8. PubMed ID: 21468526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the correlation between serum autoantibodies against aldehyde dehydrogenase 2 and thyrotropin receptor in patients with Graves' ophthalmopathy.
    Lin CC; Chiu LW; Lee PY; Chen KJ; Cheng KC
    Indian J Ophthalmol; 2024 Feb; 72(2):298-299. PubMed ID: 38273693
    [No Abstract]   [Full Text] [Related]  

  • 12. Optical Coherence Tomography Thickness Measurements of the Extraocular Rectus Muscle Tendons in Graves' Ophthalmopathy.
    De-Pablo-Gómez-de-Liaño L; Fernández-Vigo JI; Ventura-Abreu N; Troyano-Rivas J; Niño-Rueda C; Romo-López Á; Gómez-de-Liaño R
    J Pediatr Ophthalmol Strabismus; 2018 Nov; 55(6):356-362. PubMed ID: 30160297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.
    Wiersinga WM
    Lancet Diabetes Endocrinol; 2017 Feb; 5(2):134-142. PubMed ID: 27346786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves' ophthalmopathy - a 1-year follow-up: study protocol for a randomized controlled trial.
    Brammen L; Riss P; Lukas J; Gessl A; Dunkler D; Li S; Leisser A; Rezar-Dreindl S; Eibenberger K; Selberherr A; Scheuba C; Papp A
    Trials; 2018 Sep; 19(1):495. PubMed ID: 30219088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stimulatory Thyrotropin Receptor Antibodies Are a Biomarker for Graves' Orbitopathy.
    George A; Diana T; Längericht J; Kahaly GJ
    Front Endocrinol (Lausanne); 2020; 11():629925. PubMed ID: 33603715
    [No Abstract]   [Full Text] [Related]  

  • 16. Graves' disease and thyroid associated ophthalmopathy following radioiodine therapy in euthyroid multinodular goiter.
    Munigoti S; Samat A; Keston Jones M
    Thyroid; 2008 May; 18(5):585. PubMed ID: 18466082
    [No Abstract]   [Full Text] [Related]  

  • 17. Practical Guidelines Management of Graves Ophthalmopathy.
    Subekti I; Soewondo P; Soebardi S; Darmowidjojo B; Harbuwono DS; Purnamasari D; Tarigan TJE; Wisnu W; Tahapary DL; Kurniawan F; Sidik M; Nusanti S; Dewiputri S; Suharko H; Suardana GG; Suroyo I; Wulani V; Siswoyo AD; Gondhowiardjo S; Kodrat H
    Acta Med Indones; 2019 Oct; 51(4):364-371. PubMed ID: 32041923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of Graves' ophthalmopathy.
    Wiersinga WM
    Nat Clin Pract Endocrinol Metab; 2007 May; 3(5):396-404. PubMed ID: 17452966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Childhood Graves' ophthalmopathy: results of a European questionnaire study.
    Krassas GE; Segni M; Wiersinga WM
    Eur J Endocrinol; 2005 Oct; 153(4):515-21. PubMed ID: 16189172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Graves' ophthalmopathy].
    Hiromatsu Y
    Nihon Rinsho; 2006 May; Suppl 1():307-10. PubMed ID: 16776151
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.